BR0214925A - Darifenacina para uso no tratamento de urgência induzida por bexiga superativa - Google Patents

Darifenacina para uso no tratamento de urgência induzida por bexiga superativa

Info

Publication number
BR0214925A
BR0214925A BR0214925-7A BR0214925A BR0214925A BR 0214925 A BR0214925 A BR 0214925A BR 0214925 A BR0214925 A BR 0214925A BR 0214925 A BR0214925 A BR 0214925A
Authority
BR
Brazil
Prior art keywords
darifenacin
overactive bladder
emergency treatment
induced
induced emergency
Prior art date
Application number
BR0214925-7A
Other languages
English (en)
Inventor
Enrico Colli
Paul Quinn
Dzelal Serdarevic
Laurence Howard Skillern
Original Assignee
Novartis Int Pharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9927643&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR0214925(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Int Pharm Ltd filed Critical Novartis Int Pharm Ltd
Publication of BR0214925A publication Critical patent/BR0214925A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/402—1-aryl substituted, e.g. piretanide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Chemical Treatment Of Metals (AREA)
  • Diaphragms For Electromechanical Transducers (AREA)
  • Processing Of Meat And Fish (AREA)
  • Document Processing Apparatus (AREA)
  • Pyridine Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Inorganic Insulating Materials (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

"DARIFENACINA PARA USO NO TRATAMENTO DE URGêNCIA INDUZIDA POR BEXIGA SUPERATIVA". A presente invenção refere-se ao uso de darifenacina ou um derivado farmaceuticamente aceitável da mesma na fabricação de um medicamento para a redução de urgência em pacientes que sofrem de bexiga superativa.
BR0214925-7A 2001-12-14 2002-03-05 Darifenacina para uso no tratamento de urgência induzida por bexiga superativa BR0214925A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0129962.7A GB0129962D0 (en) 2001-12-14 2001-12-14 Method of treatment
PCT/IB2002/000664 WO2003051354A1 (en) 2001-12-14 2002-03-05 Method of treatment

Publications (1)

Publication Number Publication Date
BR0214925A true BR0214925A (pt) 2004-12-21

Family

ID=9927643

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0214925-7A BR0214925A (pt) 2001-12-14 2002-03-05 Darifenacina para uso no tratamento de urgência induzida por bexiga superativa

Country Status (28)

Country Link
US (3) US20030130338A1 (pt)
EP (1) EP1458376B1 (pt)
JP (3) JP2005516925A (pt)
KR (1) KR100889086B1 (pt)
CN (1) CN100488505C (pt)
AT (1) ATE341323T1 (pt)
AU (1) AU2002236141B2 (pt)
BR (1) BR0214925A (pt)
CA (1) CA2469702C (pt)
CY (1) CY1105814T1 (pt)
CZ (1) CZ301283B6 (pt)
DE (1) DE60215219T2 (pt)
DK (1) DK1458376T3 (pt)
ES (1) ES2276910T3 (pt)
GB (1) GB0129962D0 (pt)
HK (1) HK1073779A1 (pt)
HU (1) HU229908B1 (pt)
IL (2) IL162391A0 (pt)
MX (1) MXPA04005760A (pt)
NO (1) NO20042586L (pt)
NZ (1) NZ533421A (pt)
PL (1) PL206034B1 (pt)
PT (1) PT1458376E (pt)
RU (1) RU2321398C2 (pt)
SI (1) SI1458376T1 (pt)
SK (1) SK287510B6 (pt)
WO (1) WO2003051354A1 (pt)
ZA (1) ZA200404289B (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090062326A1 (en) * 2006-03-17 2009-03-05 Spindel Eliot R M3 muscarinic receptor antagonists for treatment of m3 muscarinic receptor-expressing tumors
CN101084891A (zh) * 2007-06-29 2007-12-12 北京本草天源药物研究院 一种用于口服的达非那新或其药用盐的药物制剂
CZ200845A3 (cs) * 2008-01-28 2009-09-02 Zentiva, A. S. Zpusob prípravy Darifenacinu
NZ594311A (en) * 2009-02-04 2013-05-31 Astellas Pharma Inc Pharmaceutical composition comprising tamsulosin and solifenacin for oral administration
CN102048706B (zh) * 2011-01-12 2012-02-22 山东创新药物研发有限公司 一种氢溴酸达非那新缓释片及制备方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8906166D0 (en) * 1989-03-17 1989-05-04 Pfizer Ltd Therapeutic agents
GB9518953D0 (en) * 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations

Also Published As

Publication number Publication date
PT1458376E (pt) 2007-01-31
IL162391A0 (en) 2005-11-20
CN1604777A (zh) 2005-04-06
NO20042586L (no) 2004-06-18
CN100488505C (zh) 2009-05-20
US20030130338A1 (en) 2003-07-10
CY1105814T1 (el) 2011-02-02
HK1073779A1 (en) 2005-10-21
US20090162433A1 (en) 2009-06-25
DE60215219T2 (de) 2007-10-18
PL369426A1 (en) 2005-04-18
EP1458376B1 (en) 2006-10-04
RU2004121780A (ru) 2005-08-10
ZA200404289B (en) 2005-09-28
MXPA04005760A (es) 2005-03-31
HU229908B1 (hu) 2014-12-29
RU2321398C2 (ru) 2008-04-10
DK1458376T3 (da) 2007-02-12
ATE341323T1 (de) 2006-10-15
CA2469702A1 (en) 2003-06-26
CZ2004719A3 (cs) 2005-01-12
KR20040066892A (ko) 2004-07-27
SK287510B6 (sk) 2010-12-07
DE60215219D1 (de) 2006-11-16
EP1458376A1 (en) 2004-09-22
JP2013199506A (ja) 2013-10-03
NZ533421A (en) 2007-02-23
AU2002236141B2 (en) 2007-02-01
CZ301283B6 (cs) 2009-12-30
HUP0402625A2 (hu) 2005-04-28
US8748476B2 (en) 2014-06-10
IL162391A (en) 2012-04-30
JP2005516925A (ja) 2005-06-09
JP2010024244A (ja) 2010-02-04
SI1458376T1 (sl) 2007-06-30
KR100889086B1 (ko) 2009-03-16
PL206034B1 (pl) 2010-06-30
US20070264333A1 (en) 2007-11-15
ES2276910T3 (es) 2007-07-01
WO2003051354A1 (en) 2003-06-26
GB0129962D0 (en) 2002-02-06
SK2502004A3 (en) 2004-10-05
AU2002236141A1 (en) 2003-06-30
CA2469702C (en) 2010-07-06

Similar Documents

Publication Publication Date Title
BR0213358A (pt) Uso de flibanserina
BR9911071A (pt) Preparações para aplicação de agentes antiinflamatórios, especialmente anti-sépticos e/ou agentes promotores da cura de feridas no trato respiratório superior e/ou no ouvido
BR9408378A (pt) Composto sal farmaceuticamente aceitável composição farmacêutica e processos para o tratamento de um paciente que sofreu um derrame e que sofre de uma condição de perda progressiva de função de sistema nervoso central e para melhorar os efeitos colaterais causados em um paciente por tratamento antineoplástico de doença que produz danos oxidativos
BR0205722A (pt) Formulação de liberação prolongada e método para o tratamento de um paciente que sofre de dor
HUP0301868A2 (hu) Gyógyászati készítmény, ami VIIa és XIII-as faktort tartalmaz
BR0212078A (pt) Método de tratar ou prevenir uma doença relacionada com amilóide em um paciente, composição farmacêutica, composto quìmico, e, uso de um composto
BR0115109A (pt) Agentes terapêuticos e métodos de uso dos mesmos para a modulação da angiogênese
BR9711194A (pt) Uso de agente quelante clioquinol para a fabricação de uma composição farmacêutica para o tratamento de doença de alzheimer.
BRPI0308663B8 (pt) uso de inibidores de il-18 para o tratamento e/ou prevenção de doenças vasculares periféricas
BR0207883A (pt) Composições de medicamentos à base de anticolenérgicos e inibidores de pde-iv
BR0210013A (pt) Gel oftálmico de pirenzepina
BRPI0509861A (pt) uso de simeticona em pacientes constipados
BR0214075A (pt) Dosagem unitária que compreende um análogo de prostaglandina para tratar constipação
BR0214925A (pt) Darifenacina para uso no tratamento de urgência induzida por bexiga superativa
AU7862401A (en) Pharmaceutical compostion comprising trkaig2 for use in the prevention and/or treatment of cancer
ES2177024T3 (es) Empleo de la fanquinoma para el tratamiento de la enfermedaad de alzheimer.
MD970254A (en) Use of melatonine for treatment of patients having a medicamental dependence
BR0108261A (pt) Uso de mirtazapina, método de tratamento de um distúrbio do sono em um indivìduo, e, kit para paciente para o tratamento de distúrbios do sono
KR960028907A (ko) 암환자를 치료하기 위한 세트랄린의 용도
BR0212167A (pt) Forma de dosagem oral de liberação prolongada, uso da mesma, método para a prevenção e/ou tratamento de distúrbios e perturbações médicas, e, processo para a fabricação de uma forma de dosagem de liberação prolongada
BR0208488A (pt) Agonistas de kapa-opiato para o tratamento de doenças da bexiga
BR0210007A (pt) Uso de inibidores de il-18 para tratamento ou prevenção de lesões do sistema nervoso central
BR0009327A (pt) Composição farmacêutica para a terapia de sintomas do trato urinário inferior
BR0112690A (pt) Medicamento contendo cilansetron para o tratamento de pacientes ibs masculinos não-obstipativos
BR0309055A (pt) Uso combinado de l-carnitina, acetil l-carnitina e propionil l-carnitina para o tratamento da oligoastenoteratospermia

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) DA LPI

B12B Appeal against refusal [chapter 12.2 patent gazette]
B25A Requested transfer of rights approved

Owner name: ASPEN GLOBAL INCORPORATED (MR)

B25G Requested change of headquarter approved

Owner name: ASPEN GLOBAL INCORPORATED (MR)

B65X Notification of requirement for priority examination of patent application
B65Y Grant of priority examination of the patent application (request complies with dec. 132/06 of 20061117)